Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.

Article  CAS  PubMed  Google Scholar 

Soerjomataram I, Bray F. Planning for tomorrow: global cancer incidence and the role of prevention 2020–2070. Nat Rev Clin Oncol. 2021;18(10):663–72. https://doi.org/10.1038/s41571-021-00514-z.

Article  PubMed  Google Scholar 

Berrada N, Delaloge S, André F. Treatment of triple-negative metastatic breast cancer: toward individualized targeted treatments or chemosensitization?. Ann Oncol. 2010;21 Suppl 7:vii30-vii35. https://doi.org/10.1093/annonc/mdq279.

Neuman HB, Schumacher JR, Edge SB, et al. The influence of anatomic stage and receptor status on first recurrence for breast cancer within 5 years (AFT-01). Cancer. 2023;129(9):1351–60. https://doi.org/10.1002/cncr.34656.

Article  PubMed  Google Scholar 

Grinda T, Antoine A, Jacot W, et al. Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort. Eur J Cancer. 2023;189: 112935. https://doi.org/10.1016/j.ejca.2023.05.023.

Article  PubMed  Google Scholar 

Zhu Y, Hu Y, Tang C, Guan X, Zhang W. Platinum-based systematic therapy in triple-negative breast cancer. Biochim Biophys Acta Rev Cancer. 2022;1877(1):188678. https://doi.org/10.1016/j.bbcan.2022.188678.

Dent R, Rugo HS. Most neoadjuvant chemotherapy for triple-negative breast cancer should include platinum. Lancet Oncol. 2021;22(1):27–8. https://doi.org/10.1016/S1470-2045(20)30747-6.

Yan W, Wu X, Wang S, et al. Lobaplatin-based neoadjuvant chemotherapy for triple-negative breast cancer: a 5-year follow-up of a randomized, open-label, phase II trial. Ther Adv Med Oncol. 2022;14:17588359221107112. https://doi.org/10.1177/17588359221107111.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu X, Tang P, Li S, et al. A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer. Nat Commun. 2018;9(1):832. https://doi.org/10.1038/s41467-018-03210-2.

Zhang M, Chen Y, Wu W, et al. A prospective phase II randomized study of docetaxel combined with lobaplatin versus TPF regimen induction chemotherapy followed by concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma. J Cancer Res Clin Oncol. 2023;149(20):18081–91. https://doi.org/10.1007/s00432-023-05497-1.

Article  CAS  PubMed  Google Scholar 

Lv X, Cao X, Xia WX, et al. Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22(5):716–26. https://doi.org/10.1016/S1470-2045(21)00075-9.

Article  CAS  PubMed  Google Scholar 

Zheng Y, Li Y, Liu X, et al. Multicentre Comparison of the Toxicity and Effectiveness of Lobaplatin-Based Versus Cisplatin-Based Adjuvant Chemotherapy in Oesophageal Carcinoma. Front Oncol. 2021;11: 668140. https://doi.org/10.3389/fonc.2021.668140.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang Z, Xu L, Wang H, et al. Lobaplatin-based regimens outperform cisplatin for metastatic breast cancer after anthracyclines and taxanes treatment. Saudi J Biol Sci. 2018;25(5):909–16. https://doi.org/10.1016/j.sjbs.2018.01.011.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang J, Wu R, Chen L, Yang Z, Yan D, Li M. Understanding anthracycline cardiotoxicity from mitochondrial aspect. Front Pharmacol. 2022;13: 811406. https://doi.org/10.3389/fphar.2022.811406.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dadson K, Calvillo-Argüelles O, Thavendiranathan P, Billia F. Anthracycline-induced cardiomyopathy: cellular and molecular mechanisms. Clin Sci (Lond). 2020;134(13):1859–85. https://doi.org/10.1042/CS20190653.

Article  CAS  PubMed  Google Scholar 

Kesler SR, Blayney DW. Neurotoxic effects of anthracycline- vs nonanthracycline-based chemotherapy on cognition in breast cancer survivors. JAMA Oncol. 2016;2(2):185–92. https://doi.org/10.1001/jamaoncol.2015.4333.

Article  PubMed  PubMed Central  Google Scholar 

Ding W, Li Z, Wang C, Dai J, Ruan G, Tu C. Anthracycline versus nonanthracycline adjuvant therapy for early breast cancer: A systematic review and meta-analysis. Medicine (Baltimore). 2018;97(42): e12908. https://doi.org/10.1097/MD.0000000000012908.

Article  CAS  PubMed  Google Scholar 

Najafi S, Sadeghi M, Shajari MR, Abasvandi F, Mohebi K. The comparison of anthracycline-based and non-anthracycline-based regimens in adjuvant chemotherapy of HER2-positive non-metastatic breast cancers. Contemp Oncol (Pozn). 2018;22(2):108–12. https://doi.org/10.5114/wo.2018.77048.

Article  CAS  PubMed  Google Scholar 

Chen WW, Chang DY, Huang SM, et al. The first two lines of chemotherapy for anthracycline-naive metastatic breast cancer: a comparative study of the efficacy of anthracyclines and non-anthracyclines. Breast. 2013;22(6):1148–54. https://doi.org/10.1016/j.breast.2013.07.040.

Article  PubMed  Google Scholar 

Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials. J Pharmacol Pharmacother. 2010;1(2):100–7. https://doi.org/10.4103/0976-500X.72352.

Article  PubMed  PubMed Central  Google Scholar 

R, Denkert C, Demaria S, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015;26(2):259–271. https://doi.org/10.1093/annonc/mdu450.

Litton JK, Regan MM, Pusztai L, et al. Standardized definitions for efficacy end points in neoadjuvant breast cancer clinical trials: NeoSTEEP. J Clin Oncol. 2023;41(27):4433–42. https://doi.org/10.1200/JCO.23.00435.

Article  PubMed  PubMed Central  Google Scholar 

Fan L, Strasser-Weippl K, Li JJ, et al. Breast cancer in China. Lancet Oncol. 2014;15(7):e279–89. https://doi.org/10.1016/S1470-2045(13)70567-9.

Article  PubMed  Google Scholar 

Zheng F, Du F, Wang W, et al. Updated efficacy of adjuvant epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes in early triple-negative breast cancer in phase 2 trial: 8.1-year median follow-up. Breast Cancer Res Treat. 2022;191(1):97–105. https://doi.org/10.1007/s10549-021-06401-6.

Du F, Wang W, Wang Y, et al. Carboplatin plus taxanes are non-inferior to epirubicin plus cyclophosphamide followed by taxanes as adjuvant chemotherapy for early triple-negative breast cancer. Breast Cancer Res Treat. 2020;182(1):67–77. https://doi.org/10.1007/s10549-020-05648-9.

Article  CAS  PubMed  Google Scholar 

Yu KD, Ye FG, He M, et al. Effect of adjuvant paclitaxel and carboplatin on survival in women with triple-negative breast cancer: A phase 3 randomized clinical trial. JAMA Oncol. 2020;6(9):1390–6. https://doi.org/10.1001/jamaoncol.2020.2965.

Article  PubMed  Google Scholar 

Saleh RR, Nadler MB, Desnoyers A, Meti N, Fazelzad R, Amir E. Platinum-based chemotherapy in early-stage triple negative breast cancer: A meta-analysis. Cancer Treat Rev. 2021;100: 102283. https://doi.org/10.1016/j.ctrv.2021.102283.

Article  CAS  PubMed  Google Scholar 

Sharma P, Kimler BF, O’Dea A, et al. Randomized phase II trial of anthracycline-free and anthracycline-containing neoadjuvant carboplatin chemotherapy regimens in stage I-III triple-negative breast cancer (NeoSTOP). Clin Cancer Res. 2021;27(4):975–82. https://doi.org/10.1158/1078-0432.CCR-20-3646.

Article  CAS  PubMed  Google Scholar 

Zhang L, Wu ZY, Li J, et al. Neoadjuvant docetaxel plus carboplatin vs epirubicin plus cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): Results from a multicenter, randomized controlled, open-label phase II trial. Int J Cancer. 2022;150(4):654–62. https://doi.org/10.1002/ijc.33830.

Article  CAS  PubMed  Google Scholar 

Wang W, Liu M, Ding B. Comparison of the short-term efficacy and serum markers between lobaplatin/paclitaxel- And carboplatin/paclitaxel-based adjuvant chemotherapy in patient with ovarian cancer. J Clin Pharm Ther. 2021;46(1):166–72. https://doi.org/10.1111/jcpt.13276.

Article  CAS  PubMed  Google Scholar 

Yang JS, Wang T, Qiu MQ, Li QL. Comparison of efficacy and toxicity profiles between paclitaxel/lobapoatin- and cisplatin/5-fluorouracil-based concurrent chemoradiotherapy of advanced inoperable oesophageal cancer. Intern Med J. 2015;45(7):757–61. https://doi.org/10.1111/imj.12773.

Article  CAS  PubMed  Google Scholar